

POSTER LIST

- | POSTER # | ABSTRACT & AUTHORS |
|----------|---|
| 1 | Surveillance of Mucorales resistance to azoles in the waste sorting industry: assessment of filtering respiratory protective devices and gloves
LA Caetano*, M Dias, B Almeida, C Viegas |
| 2 | <i>Aspergillus</i> spp. and azole-resistance characterization on filtering respiratory protective devices from waste sorting industry
C Viegas*, M Dias, B Almeida, P Gonçalves, C Verissimo, R Sabino, L Aranha Caetano |
| 3 | Antifungal susceptibility testing of clinical and hospital <i>Aspergillus</i> isolates at the nephrology ward of an Iranian training hospital
K Diba*, H Fakhim, K Makhdoomi, N Javanmard, S Javanmard |
| 4 | Azole- and amphotericin B-resistant <i>Aspergillus fumigatus</i> strains isolated from clinical specimens and environment in Azerbaijan
RM Huseynov*, SS Javadov, AA Kadyrova, B Bozdogan, E Oryashin, SM Askarova, BT Taqiyev, I Karalti, D Denning |
| 5 | <i>Hmg1</i> gene mutation in triazole-resistant <i>Aspergillus fumigatus</i> clinical isolates without <i>cyp51A</i> gene mutations
A Resendiz Sharpe*, R Merckx, P Verweij, J Maertens, K Lagrou |
| 6 | Emergence of azole resistant <i>Aspergillus</i> species: a consequence of environmental exposure to azole pesticides in agricultural fields of North India
P Sen*, Mukund, M Vermani, J Shankar, P Vijayaraghavan |
| 7 | Isoeugenol as a potential antifungal molecule against azole resistant environmental isolates of <i>Aspergillus fumigatus</i> and their biofilm
L Gupta*, P Sen, P Vijayaraghavan |
| 8 | Point mutations in the 14α-sterol demethylase Cyp51A or Cyp51C could contribute to azole resistance in <i>Aspergillus flavus</i>
J Lucio*, I Gonzalez-Jimenez, O Rivero-Menendez, A Alastruey-Izquierdo, T Pelaez, L Alcazar-Fuoli, E Mellado |
| 9 | Antifungal activity of novel triazole, efinaconazole, and nine comparators against 354 molecularly identified <i>Aspergillus</i> isolates, <i>in vitro</i>
H Badali*, Z Taheri Rizi, M Abastabar, M Ilkit, JF Meis, MM Davoudi |
| 10 | Susceptibility profile of Mucoralean fungi isolated from the United States to current antifungal drugs
H Badali*, C Gibas, D McCarthy, H Patterson, C Sanders, J Mele, H Fan, N.P Wiederhold |
| 11 | Clinical <i>Aspergillus</i> isolates causing aspergillosis in the last 20 years: an overview of aetiology and antifungal resistance to azoles and amphotericin B
J Serrano*, E Reigadas, A Vena, M Machado, P Muñoz, P Escribano, J Guinea |
| 12 | Susceptibility patterns of contemporary <i>Aspergillus fumigatus</i> isolates from the United States to azole antifungals
N Wiederhold*, H Badali, D McCarthy, H Patterson, C Sanders, J Mele, H Fan, C Gibas |
| 13 | Elucidating echinocandin resistance mechanisms in <i>Mucor circinelloides</i>
A Garcia*, EY Huh, SC Lee |
| 14 | The role of pentraxin-3 in the immunometabolic regulation of antifungal immunity
D Antunes*, V Aimaganianda, C Duarte-Oliveira, SM Gonçalves, C Cunha, T Gonçalves, A Carvalho |

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

- | POSTER # | ABSTRACT & AUTHORS |
|----------|--|
| 15 | Genome Wide Association Study (GWAS) for antifungal sensitivity in the opportunistic pathogen <i>Aspergillus fumigatus</i>
S Zhao*, JR Fortwendel, A Watanabe, JG Gibbons |
| 16 | CRISPR / Cas9 genome editing technology to verify the contribution of known mutations in the <i>cyp51A</i> gene and its promoter to azole resistance in <i>Aspergillus fumigatus</i>
T Umeyama*, T Inukai, M Tateno, S Yamagoe, S Takatsuka, Y Hoshino, K Ishino, Y Miyazaki |
| 17 | Hmg1 mutation conferring multi-azole resistance in <i>Aspergillus fumigatus</i>
T Arai*, T Umeyama, T Inukai, A Watanabe, Y Miyazaki, K Kamei |
| 18 | CLSI versus EUCAST for azoles susceptibility - the necessity to unify
D Pinheiro*, C Monteiro, M Maia, E Pinto |
| 19 | Antifungal susceptibility testing of clinical and community environment isolates of <i>Aspergillus</i> species
J Chander*, N Singla, M Kaur, D Aggarwal2 |
| 20 | <i>In vitro</i> evaluation of combination of Ibrexafungerp and azoles against <i>Aspergillus</i> spp. isolated from lung transplant recipients
V Jagadeesan, E Driscoll, B Hao, S Barat, K Borroto-Esoda, D Angulo, C Clancy, M Nguyen* |
| 21 | D430G mutation of CYP51A in <i>Aspergillus fumigatus</i> causes azole-resistance
H Majima, A Teppei, A Watanabe*, K Kamei |
| 22 | Antimicrobial susceptibility of <i>Aspergillus fumigatus</i> and <i>Stenotrophomonas maltophilia</i> biofilms: did they find strength in unity?
L Roisin*, E Melloul, PL Woerther, J Guillot, E Dannaoui, F Botterel |
| 23 | Evaluation of drug susceptibility of <i>Aspergillus</i> species isolated from ICU of hospitals <i>in vitro</i>
Ayat Nasrollahi Omran* |
| 24 | Mutations in <i>A. fumigatus</i> hmg1 which confer triazole resistance also alter sterol composition and increase multi-drug efflux pump gene expression
JM Rybak*, W Ge, JE Parker, SL Kelly, NP Wiederhold, VM Bruno, PD Rogers, JR Fortwendel |
| 25 | Activity of diphenyl diselenide against <i>Aspergillus</i> isolates
AM Melo*, VR Poester, L Munhoz, M Trápaga, B Roca, GB Klafke, RF Sabino, DA Stevens, MO Xavier |
| 26 | Molecular identification of <i>Aspergillus</i> isolates from Magellanic penguins
AM Melo*, RP Silva-Filho, VR Poester, A von Grol, RF Sabino, DA Stevens, MO Xavier |
| 27 | <i>In vitro</i> and <i>in vivo</i> activity of manogepix/fosmanogepix, a novel antifungal with activity against <i>Aspergillus</i> and rare molds
MD Huband, AS Ibrahim, T Gebremariam, DR Andes, PA Bien, KJ Shaw, MR Hodges* |
| 28 | Study and characterization of azole resistance in <i>Aspergillus</i> section <i>Nigri</i>
A Pérez-Cantero*, A Martin-Vicente, L López-Fernández, J Guarro, JR Fortwendel, J Capilla |
| 29 | Does monitoring <i>cyp51A</i>-mediated triazole resistance in <i>Aspergillus fumigatus</i> by pyrosequencing lead to patient benefit?
L Novak-Frazer*, D Hassan, S Hill, CB Moore, M Walczak, R Rautemaa-Richardson, MD Richardson |
| 30 | Azole resistant <i>Aspergillus fumigatus</i> from agricultural settings
M Momany*, M Brewer, SE Kang, LG Sumabat, T Melie, B Mangum |

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 31 **The role of PTX3 in innate regulation of antifungal immunity in chronic pulmonary aspergillosis**
C Duarte-Oliveira*, S Ferreira, SM Gonçalves, D Antunes, A Mantovani, C Cunha, A Carvalho
- 32 **Antifungal susceptibility profiles of olorofim (formerly F901318), and currently available systemic antifungals against mold and yeast phases of *Talaromyces marneffe***
J Zhang*, HF Liu, LY Xi, YC Chang, KJ Kwon-Chung, S Seyedmousavi
- 33 **Synergic anti-fungal activity of topical PC945, a novel inhaled azole, with systemic echinocandin on *Aspergillus fumigatus* in vitro human alveoli model**
L Daly*, KA Lucas, T Colley, P Strong, G Rapeport, K Ito
- 34 **Altered *A. fumigatus* cell wall integrity by PC945, a novel inhaled azole**
D Armstrong-James*, T Colley, P Strong, G Rapeport, K Ito
NOTE: This abstract has also been selected for Oral Presentation
- 35 **Neutrophil ROS controls fungal growth and inflammation in phagocyte NADPH oxidase-deficient zebrafish**
TJ Schoen*, EE Rosowski, BP Knox, NP Keller, A Huttenlocher
- 36 **In vivo and in vitro impairment of Th cell and neutrophil responses against *Mucor irregularis* in Card9 knockout mice**
LY Sun*, Z Wan, RY Li, J Yu
- 37 **Modulation of TREM1 signaling in macrophages infected with *Aspergillus fumigatus***
I González-Jiménez*, M Jerónimo-Albaladejo, L Bernal-Martínez, E Mellado, L Alcázar-Fuoli
NOTE: This abstract has also been selected for Oral Presentation
- 38 ***Aspergillus fumigatus* and *Pseudomonas aeruginosa* pulmonary co-exposure results in increased IL-17A, eosinophilia, and acute lung injury in allergic animals**
BN Steffan*, SA Hoselton, NP Keller, JM Schuh
- 39 **Phagocytosis of Mucorales spores by lung epithelial cells and macrophages**
U Binder*, V Naschberger, C Lass-Flörl, D Wilflingseder
- 40 **Evaluating the role of STAT3 in CD4+ T cells in susceptibility to invasive aspergillosis**
W Gohir*, L McTaggart, J Kus, T Mazzulli, D Kumar, A Humar, S Husain
- 41 **Epithelial uptake of *Aspergillus fumigatus* spores drives efficient fungal clearance in vivo and is aberrant in Chronic Obstructive Pulmonary Disease (COPD) patients**
M Bertuzzi*, GJ Howell, R Fortune-Grant, X Du, J Smith, DD Thomson, L Gregson, BA Greser, NC Motsi, N Van Rhijn, M Demirbag, EM Bignell
NOTE: This abstract has also been selected for Oral Presentation
- 42 ***Aspergillus fumigatus* cell wall promotes apical airway epithelial recruitment of human neutrophils**
MB Feldman, RA Dutko, M Wood, RA Ward, HM Leung, RF Snow, DJ de la Flor, LM Yonkers, JL Reedy, GJ Tearney, H Mou, B Hurley, JM Vyas*
- 43 **The antigens enolase, triosephosphate isomerase and heat shock protein HSS1 of *Mucor circinelloides* are recognized by sera from immunocompromised infected mice**
M Areitio, A Martin-Vicente, A Arbizu, A Antoran, L Aparicio-Fernandez, I Buldain, L Martin-Souto, X Guruceaga, A Rementeria, J Capilla, FL Hernando, A Ramirez-Garcia*
- 44 **An immunoproteomics approach to identify *Aspergillus fumigatus* protein antigens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA)**
J Macheleidt, J Kruse, P Bacher, C Grehn, A Scheffold, C Schwarz, J Springer, J Löffler, H Einsele, O Kniemeyer*, A Brakhage

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 45** **“Invasive aspergillosis on-a-chip” – a novel disease model to study *Aspergillus fumigatus* infection in the human lung**
TNM Hoang, Z Cseresnyés, S Hartung*, K Rennert, MT Figge, AS Mosig, M von Lilienfeld-Toal
NOTE: This abstract has also been selected for Oral Presentation
- 46** **Single cell approaches reveal the key dendritic cell subsets that coordinate allergic airway inflammation against the fungal allergen *Aspergillus fumigatus***
P Cook*, S Brown, E Houlder, S Khan, G Tavernier, F Svedberg, M Bertuzzi, C Forss, JE Allen, E Newell, E Bignell, A Simpson, R Niven, D Denning, A MacDonald
NOTE: This abstract has also been selected for Oral Presentation
- 47** **Mycobacterial modulation of macrophages response to *Aspergillus fumigatus***
LE Gonzales-Huerta*, T Williams, CA Evans, D Armstrong-James
- 48** **Recognition of *Aspergillus fumigatus* galactomannan by the C-type lectin receptor dectin-2**
JL Reedy*, PE Negoro, T Fontaine, H Wang, NS Khan, RA Dutko, MK Mansour, M Wuthrich, JP Latge, JM Vyas
- 49** **Uncoupling of cytokine signaling and LC3 associated phagocytosis (LAP) drives the development of invasive aspergillosis in patients with sepsis**
T Akoumianaki*, R Beau, F Pene, FL van de Veerdonk, K Vaporidi, M Netea, JP Latge, G Chamilos
NOTE: This abstract has also been selected for Oral Presentation
- 50** **Human MAIT cells as a new player in the immune response against filamentous fungi**
S Boettcher, S Hartung, MM Ruethrich*, M von Lilienfeld-Toal, S Jahreis
- 51** **Vaccine-induced immunogenicity and protection in a murine model of invasive pulmonary aspergillosis**
E Rayens*, W Rabacal, SE Kang, K Norris
NOTE: This abstract has also been selected for Oral Presentation
- 52** **Immunomodulatory properties of antifungals on human monocytes: an exploratory study**
B Henry*, W Gohir, D Kumar, A Humar, C Aguilar, S Husain
- 53** **Modelling epithelial cell – macrophage communication in fungal allergy**
S Gago*, D Weaver, M Bromley, D Denning, P Bowyer
- 54** **Antifungal liposomes targeted to fungal cells have dramatically increased efficacy**
RB Meagher*, ZA Lewis, X Lin, M Momany, S Ambati
- 55** **Why are mucormycetes resistant against voriconazole?**
M Lackner*, M V Keniya, B C Monk
NOTE: This abstract has also been selected for Oral Presentation
- 56** **Transcription factor HSF1 decreases the expression of surfactant protein-D in cells infected with *Aspergillus fumigatus***
SS Kim, HJ Kim*, GS Shin
- 57** ***Aspergillus* section *Fumigati* molds: A model lineage for studying the repeated evolution of fungal pathogenicity**
ME Mead*, JL Steenwyk, HA Raja, SL Knowles, LP Silva, GH Goldman, NH Oberlies, A Rokas

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 58** **Monitoring of mucormycosis and drug efficacy testing by the use of *M. circinelloides* reporter strains**
U Binder*, MI Navarro-Mendoza, FE Nicolas, V Naschberger, C Kandelbauer, I Bauer, J Pallua, C Lass-Flörl, V Garre
- 59** **The negative cofactor 2 complex is a master regulator of drug resistance in *Aspergillus fumigatus***
T Furukawa*, N Van Rhijn, F Gsaller, M Fraczek, S Paul, J Parker, S Kelly, R Cramer, J Latge, S Moye-Rowley, E Bignell, P Bowyer, M Bromley
NOTE: This abstract has also been selected for Oral Presentation
- 60** **The protein kinase A-dependent phosphoproteome of *Aspergillus fumigatus* reveals novel kinase targets associated with diverse and essential cellular pathways**
EK Shwab*, PR Juvvadi, S Shaheen, J Allen, G Waite, EJ Soderblom, BG Bobay, YG Asfaw, MA Moseley, WJ Steinbach
- 61** **Identification of azole resistance mechanisms in *Aspergillus lentulus***
A Martin-Vicente*, A Nywening, ACO Souza, W Ge, K Datta, KA Marr, NP Wiederhold, JR Fortwendel
- 62** **Investigation of the molecular mechanisms of copper homeostasis in *Aspergillus fumigatus***
Y Kusuya*, B Cai, D Hagiwara, T Yaguchi, H Takahashi
- 63** ***In vivo* competitive fitness profiling reveals protein kinases required for drug tolerance and adaptation of *Aspergillus fumigatus* to the murine host environment**
C Zhao, N Alfurajji, H Alshammri, E Bignell, M Bromley*
- 64** **CRISPR-Cas9 mutation and characterization of the most overexpressed transcription factor of swollen state of *Aspergillus fumigatus***
U Perez-Cuesta*, X Gुरुceaga, A Ramirez-Garcia, FL Hernando, A Abad-Diaz-de-Cerio, A Rementeria
NOTE: This abstract has also been selected for Oral Presentation
- 65** **Biosynthesis of alpha-amino-β-hydroxybutanoyl-glycyluridine: a key component in antifungal nucleoside antibiotics**
S Malek Zadeh*, TL Li
- 66** **Efficacy and safety of high-dose caspofungin in the salvage therapy of pulmonary aspergillosis**
YK Jiang, LP Huang, CW Yip, JH Cheng, CX Que, HZ Zhao, X Wang, LP Zhu, LH Zhou*
- 67** **Incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis**
C Kosmidis*, A Mackenzie, C Harris, R Hashad, F Lynch, DW Denning
- 68** **Accumulation of a novel inhaled azole, PC945, in alveolar cells in temporally neutropenic immunocompromised mice infected with *Aspergillus fumigatus***
K Ito*, Y Kizawa, G Kimura, Y Nishimoto, G Rapeport, P Strong
- 69** **Effects of inhaled PC945 on fungal load in mouth wash collected from healthy subjects in the first-in-human study (NCT02715570)**
L Daly*, K Woodward, M Coates, L Cass, P Strong, A Murray, G Rapeport, K Ito
- 70** **Topical liposomal amphotericin B (AmBisome®, Gilead Sciences Ltd, Abingdon, United Kingdom) as an adjunctive therapy in the management of post-traumatic invasive fungal infection (IFI)**
A Bapat*, C Eades, L Jones, J Cruise, K Hossenbaccus, B Cherian

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 71 **Gallium as an anti-*Aspergillus* antifungal**
DA Stevens*, M Martinez, L Yee, J Woo, V Truong, MO Xavier
- 72 **The UK National Aspergillosis Centre – Ten years' service**
C Harris*, B Bradshaw, GT Atherton, H Findon, DW Denning
- 73 **ROS-dependent and independent host-induced fungal regulated cell death in defense against invasive aspergillosis**
N Shlezinger*, TM Hohl
NOTE: This abstract has also been selected for Oral Presentation
- 74 **Interdependency of host and pathogen protein persulfidation governs disease severity in experimental and human aspergilloses**
M Sueiro-Olivares, S Gago, J Scott, Y Yu, M Strobel, C Cunha, E Kouroussis, J Zivanovic, D Thomson, P Bowyer, A Beilhack, A Carvalho, MR Filipovic, E Bignell, J Amich*
NOTE: This abstract has also been selected for Oral Presentation
- 75 **In high iron environment, pyocyanin is a major anti-*Aspergillus* molecule**
P Chatterjee*, G Sass, H Nazik, E Déziel, DA Stevens
- 76 **Palmitolealdehyde targeting conidial pigmentation and surface morphology in *Aspergillus fumigatus***
S Hoda*, L Gupta, P Vijayaraghavan
- 77 **Phenotypic analysis of *Aspergillus fumigatus* mutant lacking the P-type Na⁺-ATPase encoding gene *enaA***
T Wittayapharat*, S Foongladda, N Pinchai
- 78 **Regulatory control of epithelial damage during *Aspergillus fumigatus* infection**
SR Khan*, Z Carter, L Gregson, D Thomson, N Van Rhijn, P Papastamoulis, M Rattray, M Bromley, E Bignell
- 79 **Iron overload decreases macrophage lysosomal acidification, impairing the clearance of *Aspergillus fumigatus* conidia**
MR Kaji*, EI Matthaiou, OV Manouvakhova, JL Hsu
NOTE: This abstract has also been selected for Oral Presentation
- 80 **Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity**
SM Gonçalves*, C Duarte-Oliveira, V Aimanianda, D Antunes, G Chamilos, FL van de Veerdonk, MG Netea, JP Latgé, C Cunha, A Carvalho
NOTE: This abstract has also been selected for Oral Presentation
- 81 **Human lung colonization enables parasexual recombination in *Aspergillus fumigatus***
T Engel, PE Verweij, J van den Heuvel, D Wangmo, J Zhang, AJM Debets, E Snelders*
- 82 **Mucoricin is a Mucorales ricin-like toxin critical for mucormycosis pathogenesis**
SS Soliman, C Baldin, Y Gu, S Singh, T Gebremariam, M Swidergall, A Pikoulas, C Perske, V Venkataramani, VM Bruno, JE Edwards, Jr, SG Filler, G Chamilos, ES Vitetta, AS Ibrahim*
NOTE: This abstract has also been selected for Oral Presentation
- 83 ***Aspergillus fumigatus* – *Stenotrophomonas maltophilia* co-inoculation model on bronchial epithelial cells: antibiosis effect and inflammatory response according to bacterial strains**
C Courboulès*, E Melloul, V Balloy, L Roisin, PL Woerther, J Guillot, E Dannaoui, F Botterel

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 84 **Genetic polymorphism and mating type of *Aspergillus fumigatus* strains isolated from cystic fibrosis patients**
A Rolland, J Bigot, F Botterel, C Hennequin, J Guitard*
- 85 **The integral membrane protein stomatin plays an important role in phagocytosis of *Aspergillus fumigatus* conidia**
M Goldmann*, F Schmidt, S Jahreis, S Hartung, M Lilienfeld-Toal, T Heinekamp, AA Brakhage
- 86 **Inhibitory effect of α -bisabolol on gliotoxin production in *Aspergillus fumigatus* Af293**
Z Jahanshiri*, F Asghari-Paskiabi, M Razzaghi-Abyaneh
- 87 **Genetically distinct transcriptional circuits drive stress-adaptation and host cytotoxicity in the major mould pathogen of the human lung**
N van Rhijn*, T Furukawa, SR Khan, P Papastamoulis, F Rodenburg, R Fortune-Grant, M Rattray, M Bromley, E Bignell
- 88 ***Aspergillus flavus* biomass in maize and use of a biocontrol strategy to limit aflatoxin production**
AO Mitema*, SM Rafudeen, NA Feto, S Okoth
- 89 **Ubiquity, diversity, and functional genomics of Mucoromycota and their Betaproteobacterial endosymbionts**
J Uehling*, D Carter-House, S Putumbaka, J Stajich, J Spatafora, G Bonito, R Vilgalys
NOTE: This abstract has also been selected for Oral Presentation
- 90 **Characterization of G-protein coupled receptor NopA in *Aspergillus fumigatus***
Y Choi*, S Yoon, KS Shin
- 91 **A novel resistance mechanism to calcineurin inhibitors in *Mucor circinelloides***
S Vellanki*, RB Billmyre, A Lorenzen, M Campbell, B Turner, EY Huh, J Heitman, SC Lee
- 92 **Virus infection of *Aspergillus fumigatus* (Af) compromises Af in intermicrobial competition**
H Nazik, I Kotta-Loizou, DA Stevens*
NOTE: This abstract has also been selected for Oral Presentation
- 93 ***Aspergillus fumigatus* KnrA is an intrinsically disordered protein and functions as a potential substrate of calcineurin and protein kinase A in the cell wall integrity pathway**
PR Juvvadi*, EK Shwab, BG Bobay, DC Cole, J Allen IV, S Shaheen, G Waitt, EJ Soderblom, MA Moseley, YG Asfaw, WJ Steinbach
NOTE: This abstract has also been selected for Oral Presentation
- 94 **Analysis of *cyp51A* polymorphisms of *Aspergillus fumigatus* in Japan**
H Majima*, T Arai, A Watanabe, T Yaguchi, Y Miyazaki, K Kamei
- 95 **Pathogenic allodiploid hybrids of *Aspergillus* fungi**
JL Steenwyk*, AL Lind, LNA Ries, TF dos Reis, LP Silva, F Almeida, RW Bastos, F Rodrigues, K Lagrou, GH Goldman, A Rokas
- 96 **The deletion of *idoC* gene in *Aspergillus fumigatus* affects its normal growth and resistance to different stresses**
X Guruceaga*, U Perez-Cuesta, A Martin-Vicente, A Abad-Diaz-de-Cerio, FL Hernando, JR Fortwendel, A Ramirez-Garcia, A Rementeria
- 97 **Epigenetic mechanisms of azole stress adaptation in *Aspergillus fumigatus***
M Aruanno*, S Gozel, D Bachmann, JE Parker, A Coste, D Sanglard, F Lamoth
- 98 **Investigation of adaptation to hypoxia in *Aspergillus fumigatus***
C Bian*, Y Kusuya, D Hagiwara, A Watanabe, H Takahashi

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 99 **Study on gene expression of Na⁺-ATPase encoding gene *enaA* during stress response in *Aspergillus fumigatus***
N Pinchai*
- 100 **Navigating barriers to understand early endosome trafficking in *Aspergillus fumigatus***
BD Bieger*, AM Rogers, MJ Egan
- 101 **Fungal contamination rates of water in Lagos University Teaching Hospital water distribution systems**
KS Olawale*, FT Ogunsola, RF Peters, RO Oladele, DW Denning
- 102 **Probable hospital sources of *Aspergillus* species isolated from bedfast cases**
K Diba*, N Moshiri, M Rabiepour, F Jangi
- 103 **Allergic bronchopulmonary aspergillosis, *Aspergillus fumigatus* chronic colonization and cystic fibrosis transmembrane conductance regulator genotype; a complicated relationship in cystic fibrosis patients**
M Noni*, A Katelari, S Doudounakis, V Spoulou
- 104 **The clinical spectrum of *Aspergillus fumigatus* diseases in cystic fibrosis**
M Noni*, A Katelari, S Doudounakis, V Spoulou
- 105 ***Aspergillus terreus* infection in a patient with cardiac implantable electronic device**
AB Xess*, R Bir, G Singh, I Xess
- 106 **Mucormycosis: Emerging and devastating fungal infection, continuing further one-year experience from tertiary care hospital, northern India**
J Chander*, N Singla, N Gulati, A Bhagat, G Dhanda, RPS Punia, D Aggarwal, AK Attri, A Dass
- 107 **Clinical spectrum and antifungal susceptibility profile of *Aspergillus terreus* species complex: a single centre study from India**
G Singh*, I Xess, P Mani, A Iram, J Sachdev, A Xess, A Mohan, M Soneja, R Seth
- 108 **Prevalence of *Aspergillus fumigatus* and *Aspergillus flavus* in soil of agricultural fields in Nepal**
U Shrestha Khwakhali*
- 109 **Diagnosis of female genital tuberculosis using Xpert MTB/RIF**
SK Dhami*, HS Bisht
- 110 **Clinical evaluation of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease**
JS Suzuki*, KT Takeda, ON Narumoto, HN Nagai, HM Matsui
- 111 **Re-administration of voriconazole after hepatic toxicity**
O Narumoto*, J Suzuki, K Takeda, A Tamura, H Nagai, H Matsui
- 112 **Fungal burden in a Clinical Pathology Service of a Central Hospital in Lisbon**
AQ Gomes*, B Almeida, R Lourenço, M Dias, LA Caetano, C Viegas
- 113 **An exotic case of palatal entomophthoromycosis due to *Conidiobolus coronatus***
V Hallur, M Sable, G Purohit, P Parida, V Deshmukh*
- 114 **The incidence of pulmonary aspergillosis in patients with cystic fibrosis in Russian Federation**
YI Kozlova, YV Borzova, TA Stepanenko, AV Orlov, OV Aak, TS Bogomolova, SM Ignatyeva, NV Vasilyeva, NN Klimko*

NOTE: This abstract has also been selected for Oral Presentation

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 115** **A difficult-to-treat case of mucormycosis**
S Kömür*, S Paydaş, M Dağkiran, A Uğuz, B Kurtaran
- 116** **New perspective: evaluation of mucormycosis cases with European QUALity (EQUAL) score**
S Kömür*, A Ulu, A Uğuz, AS İnal, F Kuşcu, M Dağkiran, HD Dinçyürek, B Kurtaran, Y Taşova
- 117** **Prospective evaluation of quality of life and Aspergillus IgG in tuberculosis (TB) patients in Lagos, Nigeria**
RO Oladele*, T Gbajabiamila, FT Ogunsola, R Longe-Peters, S Skevington, DW Denning
NOTE: This abstract has also been selected for Oral Presentation
- 118** **Fatal mucormycosis and aspergillosis in an atypical host: what do we know about mixed invasive mold infections?**
DF Farmakiotis*, WC Cao, JD Donahue
- 119** ***Aspergillus fumigatus* rhinocerebral abscess in a diabetic patient**
D Pinheiro*, C Monteiro, E Pinto
- 120** **Environmental distribution of *Aspergillus terreus* species complex in Tyrol, Austria**
AM Dietl*, R Vahedi-Shahandashti, C Lass-Flörl
- 121** **Environmental *Aspergillus* and Mucorales species in beach-sand of Israeli Mediterranean coast: possible impact on human health**
M Frenkel, Y Yunik, S Blum, D Elad, E Sionov, E Segal*
- 122** **Design of a phase 2 study to evaluate fosmanogepix (APX001), a novel antifungal, for the treatment of patients with invasive mold infections (IMI) with limited treatment options**
MR Hodges*, J Maertens, BJ Kullberg, JR Perfect, SE Hazel, H Schlamm, OA Cornely
- 123** **Clinical and microbiological characterization of influenza associated aspergillosis in Southern Taiwan**
HC Wang, CT Cia, MI Hsieh, PC Chou, CJ Wu*, WC Ko
- 124** **Using social media to expand the impact of LIFE Worldwide in fungal medical education**
BH Bradshaw*, GT Atherton, H Findon, C Harris, DW Denning, JL Rodriguez Tudela
- 125** **Disseminated invasive aspergillosis. Results of retrospective analysis of the large register**
O Shadrivova, S Khostelidi, E Desyatik, E Shagdileeva, O Uspenskaya, M Popova, A Volkova, Y Borzova, T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*
- 126** **Clinical and laboratory features of invasive aspergillosis in HIV-positive patients**
O Shadrivova, O Leonova, D Bubnova, A Volkova, M Popova, T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*
- 127** **Invasive aspergillosis in adult non-hematological patients**
O Shadrivova, M Tonkoshkur, E Desyatik, A Volkova, M Popova, S Ermolova, T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*
- 128** **Clinical and laboratory features of invasive aspergillosis in patients with multiple myeloma**
O Shadrivova, V Pivovarova, Y Chudinovskikh, T Shneyder, O Uspenskaya, M Popova, A Volkova, E Desyatik, Y Borzova, S Ignatyeva, T Bogomolova, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 129** **The combination of invasive aspergillosis with other mycoses in adult hematologic patients**
O Shadrivova, S Khostelidi, E Shagdileeva, Y Chudinovskikh, M Popova, A Volkova,
E Desyatik, S Ignatyeva, T Bogomolova, L Zubarovskaya, B Afanasyev, N Vasilyeva,
N Klimko*
- 130** **Invasive aspergillosis in elderly patients**
O Shadrivova, S Khostelidi, E Desyatik, A Volkova, M Popova, O Uspenskaya, T Shneyder,
T Bogomolova, S Ignatyeva, L Zubarovskaya, B Afanasyev, N Vasilyeva, N Klimko*
- 131** **Cases of successful treatment of chronic pulmonary aspergillosis in patients after
destructive pneumonia**
M Zakhvatkina, O Shadrivova, E Desyatik, N Nikolaeva, Y Borzova, T Bogomolova,
S Ignatyeva, N Vasilyeva, N Klimko*
- 132** **Mucormycosis in large cohort of pediatric and adult patients after hematopoietic stem cell
transplantation & chemotherapy**
M Popova*, Y Rogacheva, A Volkova, A Frolova, I Markova, A Shvetcov , I Nikolaev,
S Ignatieva, T Bogomolova, A Gevorgayn, O Paina , T Bykova , E Darskaya, O Goloshchapov,
M Vladovskaya, S Bondarenko, I Moiseev, L Zubarovskaya , N Klimko, B Afanasyev
- 133** **Features of invasive aspergillosis in B-cell lymphoma patients: risk factors, diagnostics,
treatment and survival**
J Chudinovskikh, T Semiglazova, M Popova, O Shadrivova, I Zuzgin, S Ignatyeva,
T Bogomolova, L Filatova, E Cherkasova, N Klimko*
- 134** **Case of successful treatment of invasive aspergillosis in girl with systemic lupus
erythematosus**
O Kozlova, M Kostik, P Muratov, T Bogomolova, S Ignatieva, N Klimko*
- 135** **Invasive aspergillosis in pediatric patients with malignancies: retrospective register review**
Y Dinikina, O Shadrivova, M Belogurova, S Ignatyeva, T Bogomolova, E Boichenko,
N Klimko*
- 136** **Chest computed tomography (CT) scan features of chronic pulmonary aspergillosis (CPA)**
NG Nikolaeva*, OV Shadrivova, NN Klimko
- 137** **The global impact of *Aspergillus* infection on COPD**
E Hammond*, C McDonald, J Vestbo, DW Denning
- 138** **Systemic aspergillosis secondary to acute enterocolitis in foals**
M Mousquer, RP Souza, L Rafael, J Bonel, AM Melo*, AG Reis, RO Faria, DA Stevens,
MO Xavier, CEW Nogueira
- 139** **Rhinocerebral mucormycosis in a newly diagnosed type I diabetic: a case report at a
tertiary facility in Northern Nigeria**
J Ejembi*, IM Adeyemo, I Okpe, HM Umar, F Bello, AG Bakari, O Jimoh, AT Olayinka
- 140** **A case of invasive pulmonary aspergillosis occurring in a non-neutropenic patient at a
tertiary facility in North-West Nigeria**
J Ejembi*, M Abdulazeez, R Oladele, I Gembu, AT Olayinka, AI Mamman
- 141** ***Aspergillus* keratitis in the center of Tunisia: a 37-year retrospective study**
S Ismail, H Chouaieb, A Yaacoub, M Ben Saif, M Ben Said, A Fathallah*
- 142** **Epidemiological trends in *Aspergillus* spectrum involved in human aspergillosis in Sousse
region, Tunisia: a 33-year retrospective study (1986-2019)**
H Chouaieb, S Ismail, M Ben Saif, A Yaacoub, Y Bahri, F Saghruni, M Ben Said,
A Fathallah*

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 143 Pulmonary mucormycosis in diabetic patients: a report of 4 cases**
I Dhib, A Yaacoub, F Belazreg, S Ismail, A Letaief, H Hmouda, A Fathallah*
- 144 Rhinocerebral mucormycosis in central Tunisia: a study of 15 cases**
I Dhib, A Yaacoub, H Chouaib, S Ismail, M Bellakhdhar, A Garrouche, M Abdelkefi, A Fathallah*
- 145 Various clinical forms of ear mucormycosis: report of four cases**
A Yaacoub, Y Barhi, A Meherzi, H Chouaib, W Kermani, M Abdelkefi, A Fathallah*
- 146 Primary cutaneous aspergillosis: report of two cases**
S Ismail, A Yaacoub, H Chouaieb, H Regaieg, N Ben Sayed, N Abdessayed, W Hachfi, Y Ben Youssef, M Mokni, A Letaief, A Khlif, A Fathallah*
- 147 Galactomannan detection in bronchoalveolar lavage fluids: a diagnostic approach for fungus ball in patients with pulmonary tuberculosis?**
MT Hedayati*, M Gheisari, N Basharadz, J Yazdani Charati, MS Mirenayat, M Pourabdollah, S Ansari, V Mortezaee, M Abastabar, J Jafarzadeh, I Haghani
- 148 PCR based methods for diagnosis of mucormycosis**
M Pandey*, R Agarwal, G Singh, R Kumar, V P Jyotsna, A Iram, P Mani, A Xess, I Xess
- 149 Mucorales-specific quantitative PCR on peripheral blood is a sensitive and early diagnostic marker for invasive mucormycosis**
T Mercier*, M Reynders, K Beuselinck, E Guldentops, J Maertens, K Lagrou
- 150 Defining new risk factors for *Aspergillus* bronchitis**
S Gago*, D Weaver, S Anees-Hill, C Harris, CB Moore, MD Richardson, MJ Bromley, P Bowyer, DW Denning
- 151 A high frequency of azole resistance due to G54 mutations in *Aspergillus fumigatus* from bronchoalveolar lavage of chronic respiratory diseases patients in a referral chest hospital in Delhi, India using the AsperGenius® Resistance real-time PCR assay and a new G54/M220 assay**
A Singh*, KK Mahto, PK Singh, K Jain, JF Meis, A Chowdhary
- 152 Mitochondrial markers a future direction for the detection, identification and quantification of mucormycetes?**
R Caramalho, L Madl, K Rosam, G Rambach, C Speth, J Pallua, T Larentis, R Araujo, A Alastruey-Izquierdo, C Lass-Flörl, M Lackner*
- 153 Evaluation of serum *Aspergillus* IgG level in pulmonary tuberculosis patients in Indonesia**
F Setianingrum*, A Rozaliyani, R Adawiyah, R Syam, M Tugiran, CYI Sari, F Nandipinto, J Ramnath, D Handayani, E Burhan, MC Rumende, AR Arifin, R Wahyuningsih, RR Richardson, DW Denning
- 154 Molecular detection of *Aspergillus* in respiratory samples collected from patients with suspicion of respiratory fungal infection**
M Oliveira, H Simões, C Verissimo, R Sabino*
- 155 Validation of diagnostic criteria in pathological or physician-diagnosed cases with allergic bronchopulmonary aspergillosis/mycosis**
KA Asano*, HA Hebisawa, TI Ishiguro, NT Takayanagi, JS Suzuki, JT Tanaka, MT Taniguchi, KK Kamei, TO Oguma
- 156 Local experience feedback on performing routinely the PCR Mucorales on blood samples in hematological patients**
AP Bellanger*, A Berceanu, E Scherer, E Daguindeau, Y Desbrosses, L Millon

9th ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS

27 - 29 February 2020 - Lugano, Switzerland

POSTER

ABSTRACT & AUTHORS

- 157** **Development of main spectral profiles database for MALDI-identification of common aspergillosis causative agents from the colonies obtained in liquid medium**
NV Vasilyeva*, IA Riabinin, LV Alieva, YV Mikhaylova, YV Borzova, TV Bogdanova, AY Alexeyev, NP Remnyeva, VM Kaschuba, OA Schurpitskaya, TS Bogomolova, GA Chilina
- 158** **Relationship between clinical and environmental *Aspergillus* isolates from the high-risk areas of a tertiary care hospital**
I Xess*, M Mahapatra, P Mani, G Singh, A Mohan, R Kumar, S Bakshi, M Soneja, M Pandey
- 159** **Multiplex real time PCR for detection and identification of *Aspergillus* and *Mucormycetes* spp. in native and formalin-fixed paraffin-embedded tissue samples of patients with mycosis**
SM Ignatyeva*, VA Spiridonova, TS Bogomolova, YL Avdeenko, OV Shadrivova, YV Borzova, IS Zuzgin, JA Chudinovskikh, MO Popova, OS Uspenskaya, NN Klimko, NV Vasilyeva
- 160** **Adaptation of a quantitative mucormycosis PCR to a fast-protocol for a same-day result**
AT Coste*, R Brouillet, Z Naseri, K Jatou
- 161** **The potential of early low-dose chest computed tomography (CT) plus pulmonary angiography (CTPA) to improve management of invasive mould disease (IMD) in high-risk patients with hematological malignancies: a pilot study**
M Stanzani*, C Sassi, C Sartor, G Battista, PE Coppola, RE Lewis
- 162** **Establishment of a whole blood ELISA to quantify T-cellular cytokine release in response to *Aspergillus fumigatus* antigens**
CD Lauruschkat*, L Page, S Etter, E Schnack, F Ebel, J Loeffler, S Wurster
- 163** **Etanercept treatment and monocytopenia increase the risk for invasive aspergillosis in patients after allogeneic stem cell transplantation**
T Zoran*, M Weber, J Springer, PL White, J Bauer, A Schober, C Löffler, B Seelbinder, K Hünninger, O Kurzai, A Scherag, S Schäuble, CO Morton, H Einsele, J Linde, J Löffler
- 164** **Burden of serious fungal infections in Togo**
AM Dorkenoo, BK Ocansey*, E Sossou, F Lack, A Adjetej-Toglozombio, DW Denning
- 165** **NIAID Resources Poster**
D Love